Skip to content

Abstract 14489: GLP-1 Receptor Agonists vs. SGLT2 Inhibitors and Risk of Atrial Fibrillation in Patients with Obstructive Sleep Apnea and Obesity: A Propensity-Matched Analysis

Nov 2026 · Circulation · 0 citations

Abstract

Introduction: Obstructive sleep apnea (OSA) and obesity are established risk factors for atrial fibrillation (AF) through shared mechanisms including chronic intermittent hypoxia, sympathetic activation, and atrial remodeling. GLP-1 receptor agonists (GLP-1 RA) and SGLT2 inhibitors (SGLT2i) are increasingly used in this population, yet their comparative effects on AF and cardiovascular outcomes remain unclear. Hypothesis We hypothesized that GLP-1 RA use is associated with lower risk of incident AF compared to SGLT2i in patients with OSA and obesity, with concurrent benefits across secondary cardiovascular outcomes. Methods: Using the TriNetX Global Collaborative Network (171 healthcare organizations), we identified adults aged 18-85 with OSA and obesity who initiated GLP-1 RA (N=320,923) or SGLT2i (N=127,974) after January 2012, with mutual exclusion of the other drug class (Figure 1). Outcomes were analyzed at 1, 3, and 5 years. Propensity score matching (PSM) on 50 covariates (demographics, diagnoses, medications, lab values, CPAP use) yielded 72,778 matched pairs. Primary outcome was incident AF (ICD-10: I48.0-I49.2, I48.91). Secondary outcomes included pulmonary hypertension (PH), myocardial infarction (MI), heart failure (HF), and all-cause mortality. Results: After PSM, cohorts were well-balanced (mean age 62 years, 59% male, 72% T2DM). GLP-1 RA was associated with significantly lower risk of incident AF at 1 year (HR 0.682, 95% CI 0.637-0.731), 3 years (HR 0.726, 95% CI 0.691-0.764), and 5 years (HR 0.761, 95% CI 0.727-0.797; all p<0.001) (Figure 2). For secondary outcomes at 5 years, GLP-1 RA demonstrated markedly lower risk of PH (HR 0.603, 95% CI 0.573-0.635), MI (HR 0.696, 95% CI 0.660-0.734), HF (HR 0.798, 95% CI 0.764-0.833), and all-cause mortality (HR 0.870, 95% CI 0.839-0.902; all p<0.001). The protective effect of GLP-1 RA was most pronounced at 1 year and attenuated modestly over time, yet remained significant across all timepoints. Conclusion: In patients with OSA and obesity, GLP-1 RA use is associated with substantially lower risk of incident AF and major cardiovascular outcomes compared to SGLT2i across 1-, 3-, and 5-year follow-up. These findings support a preferential cardioprotective role for GLP-1 RA in this high-risk population and warrant further investigation through prospective trials.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.